Skip to content
AnalystLens

Corteva, Inc. 8-K Report, Financial Results (Feb 5, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 5, 2025
Period End
February 5, 2025
Security
CTVA
In the record · 2019–202610-K710-Q238-K85

CTVA filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 85 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’21Feb ’21
  2. Restructuring8-K · Aug ’22Aug ’22
  3. Impairment8-K · Nov ’23Nov ’23
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed February 5, 2025. Cited figures are marked; the original filing is the authoritative source.

Corteva's fourth-quarter and full-year 2024 results, furnished under Item 2.02 on February 5, 2025, show a company with a strong finish to a flat year.

Q4 net sales rose 7% to $3.98Ba (organic +13%), driven by a 17% volume gain led by Brazil's Safrinha corn and Latin American crop protection demand. Q4 GAAP results were still a loss from continuing operations of $(50)M, or $(0.08) per share, though this improved sharply from the prior year, while Operating EBITDA rose 36% to $525M and Operating EPS reached $0.32. The Q4 GAAP loss was weighed down by a $120M tax charge tied to a valuation allowance on a Brazilian seed entity and $89M of restructuring charges.

For full-year 2024, net sales fell 2% to $16.9Bb, though organic sales grew 1%. GAAP EPS from continuing operations was $1.22 and Operating EPS was $2.57, down 4% from 2023. Operating EBITDA was roughly flat at $3.4B.

Free cash flow improved 40% to $1.7Bc, supporting $1.5B in cash returned to shareholders. Crop Protection faced continued price pressure, with prices down 5% for the year, while Seed price rose 3%. Full-year 2025 guidance was refined for currency headwinds from a stronger U.S. dollar, with net sales expected at $17.2-17.6B, Operating EBITDA at $3.6-3.8B, and Operating EPS at $2.70-2.95.

Management also plans about $1.0Bd of share repurchases in 2025 and expects $150-165M of pre-tax restructuring charges as crop protection network optimization continues through 2026. Investors should weigh the strong volume momentum and cash generation against persistent Latin American pricing pressure, currency drag, and ongoing restructuring costs.

02—Key points

Key Highlights

  1. Q4 2024 net sales rose 7% to $3.98B, with organic sales up 13% and volume up 17%, led by Brazil's Safrinha corn and Latin American crop protection.
  2. Q4 2024 Operating EBITDA increased 36% to $525M, with roughly 280 basis points of margin expansion; Operating EPS rose 113% to $0.32.
  3. GAAP Q4 loss from continuing operations of $(50)M included a $120M tax valuation allowance charge on a Brazilian seed entity and $89M of restructuring charges.
  4. FY2024 net sales declined 2% to $16.9B (organic +1%); GAAP EPS from continuing operations was $1.22 and Operating EPS was $2.57.
  5. Free cash flow improved 40% to $1.7B, and total cash returned to shareholders reached $1.5B.
  6. FY2025 guidance: net sales $17.2-17.6B, Operating EBITDA $3.6-3.8B, Operating EPS $2.70-2.95, with the outlook refined for a stronger U.S. dollar.
  7. Plans to repurchase about $1.0B of shares in 2025 and expects $150-165M of pre-tax restructuring charges for crop protection network optimization.

03—Questions

Frequently Asked Questions

  1. Why did GAAP earnings remain negative in Q4 2024 even though Operating EBITDA grew strongly?

    The Q4 GAAP loss from continuing operations of $(50)M reflected $89M of restructuring and asset-related charges and a $120M tax charge from a valuation allowance on a Brazilian seed entity's deferred tax asset. Operating EBITDA excludes these significant items, along with depreciation, amortization, interest, and foreign exchange losses, which is why it rose 36% to $525M.

  2. How did the top line perform, and what drove the growth?

    Full-year net sales fell 2% to $16.9B, but organic sales grew 1%. Q4 growth was driven by a 17% volume increase, primarily from Brazil's expected Safrinha corn planted area and new Latin American crop protection products. Pricing was a headwind, down 4% in Q4 and down 5% in Crop Protection for the full year.

  3. What is the outlook for 2025, and what risks does it reflect?

    Management guided to 2025 net sales of $17.2-17.6B (about 3% growth at midpoint), Operating EBITDA of $3.6-3.8B (about 10% growth at midpoint), and Operating EPS of $2.70-2.95. The company cited persistent crop protection price pressure and currency headwinds from a strong U.S. dollar. Operating guidance excludes significant items, and Corteva does not provide a reconciliation to GAAP for forward-looking non-GAAP measures.

  4. How strong is the company's cash generation and capital return program?

    Cash from continuing operations rose 27% to $2.3B and free cash flow rose 40% to $1.7B in 2024. The company returned $1.5B to shareholders, including $1.0B of share repurchases, and plans about $1.0B of buybacks in 2025.

  5. What restructuring activity should investors expect?

    Corteva is restructuring its Crop Protection manufacturing and external partner network, with activities expected to be substantially complete in 2026. The company expects $150-165M of net pre-tax restructuring charges in 2025, which are excluded from Operating EBITDA and Operating EPS but will affect GAAP results.

04—Continue

← View all 8-K filings